Loading...
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab...
Na minha lista:
| Udgivet i: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8175839/ https://ncbi.nlm.nih.gov/pubmed/34123391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20552173211013831 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|